3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Abbas Rana of BCM, Rebecca C. Vaught of Van Heron Labs, and Patrick Scateni of Hypertec. Photos courtesy

Editor's note: Welcome to another Monday edition of Innovators to Know. Today I'm introducing you to three Houstonians to read up about — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.

Abbas Rana, associate professor of surgery at Baylor College of Medicine

The NIH grant goes toward TransplantAI's work developing more precise models for heart and lung transplantation. Photo via BCM

The National Institute of Health has bestowed a Houston medtech company with a $2.2 million Fast-Track to Phase 2 award. InformAI will use the money for the product development and commercialization of its AI-enabled organ transplant informatics platform.

TransplantAI solves that problem, as well as organ scarcity and inefficiency in allocation of the precious resource.

The NIH grant goes toward developing more precise models for heart and lung transplantation (kidney and liver algorithms are further along in development thanks to a previous award from the National Science Foundation), as well as Phase 2 efforts to fully commercialize TransplantAI.

"There is an urgent need for improved and integrated predictive clinical insights in solid organ transplantation, such as for real-time assessment of waitlist mortality and the likelihood of successful post-transplantation outcomes," according to the grant’s lead clinical investigator, Abbas Rana, associate professor of surgery at Baylor College of Medicine. Read more.

Rebecca C. Vaught, founder and CEO of Van Heron Labs

Van Heron Labs, founded at TMC, raised a $1.1 million seed round led by FoodLabs. Photo via LinkedIn

A biotech company that was founded at the Texas Medical Center in Houston has raised fresh funding to support its goal of innovating new technologies for a healthier humanity.

Van Heron Labs, based in Huntsville, Alabama, raised a $1.1 million seed round led by FoodLabs, a European investor and venture studio for food, health, and climate. The startup taps into genomics, bioinformatics, artificial intelligence, and nanotechnology to improve how cells are cultured and harnessed with the mission to address critical industrial and global challenges with biotechnology.

“Van Heron Labs looks forward to using the generous support and funding from FoodLabs to advance our goal of making biological innovation better, faster, and cheaper," Rebecca C. Vaught, founder and CEO of Van Heron Labs, says in a news release. "By fueling the new bio-economy, we feel that our customers can optimize their systems and bring technologies to overcome critical global challenges to market." Read more.

Patrick Scateni, vice president of global sales of Hypertec

The hardware upgrades more than “double the effective horsepower of DUG’s Houston data center.” Photo via LinkedIn

An Australia-based company has launched a major upgrade of its Houston data center with sustainability in mind.

DUG Technology announced it's increased the company’s high performance computing (HPC) capabilities and also reinforced its commitment to sustainable innovative technology. The company announced its latest investment in 1500 new AMD EPYCTM Genoa servers, which has 192 cores and 1.5 terabytes of DDR5 memory each. Quebec-based IT solution company Hypertec provided the immersion-born hardware.

“DUG’s decision highlights the unmatched technological advancements and superior performance of Hypertec immersion-born products, which are setting a new benchmark in the industry,” Hypertec’s Patrick Scateni, vice president of global sales says in a news release. Read more.

Van Heron Labs, founded at TMC, raised a $1.1 million seed round led by FoodLabs. Photo via Getty Images

Houston-founded startup raises $1.1M seed to fuel growth in bioeconomy

fresh funding

A biotech company that was founded at the Texas Medical Center in Houston has raised fresh funding to support its goal of innovating new technologies for a healthier humanity.

Van Heron Labs, which was founded by Vaught, Alec Santiago, and Nithin Parsan in February 2020, originally launched with its cell-focused platform to support COVID-19 pandemic response. The company's cell-based applications also include cancer therapeutics and food and materials production.

“We are excited to lead the funding round in Van Heron Labs, as we firmly believe that their innovative approach to optimizing cellular nutrition has the potential to revolutionize multiple industries, including biopharma, biomanufacturing, foodtech, and agriculture,” Julius Strauss, investor at FoodLabs, says. “We are excited to be partnering with Dr. Rebecca Vaught and her team as they continue to push the boundaries of innovation in the bio-economy.”

The funding will go toward supporting existing and new product lines.

Van Heron Labs' automated flagship platform uses bioinformatics and advanced AI tools to discover the optimal cellular fuel. This information can be used to personalize the customers’ culture media to provide more excellent quality, efficiency, and scalability, per the company.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME